SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode is pleased to announce that they have been accepted for listing on the Taiwan Emerging Market Stock Exchange (ticker symbol 6598).
As a registered Cayman Island corporation with facilities in the United States and Taiwan, Applied BioCode designs, develops, and commercializes innovative high value automated products for the Molecular Diagnostics medical industry. Their products and services will revolutionize the industry providing hospitals and reference laboratories with the ability to perform rapid, high volume, low cost molecular diagnostic testing for multiple pathogens. The Applied BioCode automated system* with multiplexing testing capability will allow earlier intervention of therapy by physicians, provide improved outcomes for patients, and globally lower overall healthcare costs.
Dr. Winston Ho, President of Applied BioCode, stated that he is very pleased that they have qualified for acceptance onto the Taipei Stock Exchange.
“This will enable Applied BioCode to gain access to additional capital in order to accelerate the commercialization of the BioCode MDx 3000 High Volume Molecular Diagnostics System* with 18 plex Gastrointestinal Panel into the US market and we anticipate FDA clearance later this year. This is an exciting time for Applied BioCode and I am looking forward to the positive impact of our products on both patients and healthcare systems worldwide,” said Dr. Ho.
About Applied BioCode
Applied BioCode designs, develops, manufactures, and markets Barcoded Magnetic Beads (BMB) and detection systems to facilitate highly multiplexed nucleic acids or protein detection assays. The BMB technology offers up to 4,096 unique digital barcodes for multiplex analysis with unmatched decoding accuracy. Our easy-to-use BioCode systems employ steady state detection without requiring flow cytometers that are prone to channel blockage or sample cross contamination. The systems are well suited for clinical diagnostic applications such as detection of infectious pathogens, drug resistance markers, cancer markers and mutation analysis, as well as specific applications for the life science research and agricultural testing markets. For more information, please visit the company’s website at www.apbiocode.com
*Under development.
